{
  "id": "63f02ceaf36125a426000015",
  "type": "summary",
  "question": "Which are the targets of Tirzepatide?",
  "ideal_answer": "Tirzepatide is a dual incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)  receptor agonist in the form of a synthetic linear peptide.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35658024",
    "http://www.ncbi.nlm.nih.gov/pubmed/35593668",
    "http://www.ncbi.nlm.nih.gov/pubmed/35651477"
  ],
  "snippets": [
    {
      "text": "Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651477",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "he efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658024",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35593668",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the form of a synthetic linear peptide; its acylation technology allows it to bind to albumin, thus making it possible to dose the drug once a week. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35593668",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}